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Innate immunityTrim5α is a host antiviral protein that recognizes incoming retroviral capsids in the cytoplasm and prevents
productive infections. Although present in most mammals, the state of the Trim5 gene is dynamic in that
primates have one copy with several splice variants, while rodents and cows have multiple copies. Mouse
Trim30 (one of the mouse Trim5α homologs) has been shown to negatively regulate NF-kappaB activation by
targeting upstream signaling intermediates TAB2 and TAB3 for degradation. We show that human Trim5α
also affects levels of TAB2, resulting in abrogation of TAB2-dependent NF-kappaB activation. Surprisingly,
unlike mouse Trim30, human and rhesus Trim5α are able to activate NF-kappaB-driven reporter gene
expression in a dose-dependent manner. We show that Trim5α uses distinct domains for the distinct abilities
of affecting TAB2 levels, regulating NF-kappaB, and recognizing retroviral capsids. Our results demonstrate
functions of Trim5α that are not dependent on recognizing the retroviral capsid.inson Cancer Research Center,
).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Trim5α is a host antiviral protein initially identiﬁed as a factor in
rhesusmacaquemonkeys that blocks human immunodeﬁciency virus-1
(HIV-1) infection during an early post-entry stage (Stremlau et al.,
2004) (reviewed in Towers, 2005). Proteins suchasTrim5α that are part
of the interface between host and pathogen undergo adaptive evolution
which manifests itself in the form of a higher rate of nonsynonymous
changes compared to synonymous changes (Holmes, 2004). Analysis of
rapidly evolving codonsamongprimateTrim5αorthologshas identiﬁed
amino acids that determine the speciﬁcity of Trim5α towards retroviral
capsids (Sawyer et al., 2005). These amino acids are mostly located in
the PRY-SPRY domain due to interactions between this domain and
retroviral capsids (Sawyer et al., 2005; Liu et al., 2005; Stremlau et al.,
2004; Sebastian and Luban, 2005).
While the PRY-SPRY domain has been rapidly evolving, the other
domains of the protein including the RING, Bbox, and coiled-coil (RBCC)
domains (Nisole et al., 2005;Reymondet al., 2001) showmore sequence
conservation (Sawyer et al., 2005, 2007; Tareen et al., 2009; Johnson and
Sawyer, 2009). The reasons for the evolutionary constraint in these
more conserved domains could be due to maintaining structuralintegrity, catalytic functions, and/or other unknown functions. For
example, the RING and Bbox domains of Trim5α perform effector
functions and contain characteristic zinc-ﬁnger motifs (Stremlau et al.,
2004; Perez-Caballero et al., 2005), while the coiled-coil domain allows
multimerization (Mische et al., 2005). Although some of the constraint
in the RBCC domains of Trim5α could be explained by the need to
maintain functional zinc-ﬁnger motifs in the RING and Bbox and by the
need to maintain the ability to multimerize through the coiled coil
domain, the question still remains whether Trim5α harbors other
unknown functions in addition to its role as an antiviral restriction
factor.
The Trim5 locus has undergone expansions on more than one
occasion, such that in cows and rodents, there have been two
independent paralogous expansions of Trim5 genes (reviewed in
Johnson and Sawyer, 2009). Cows have up to ﬁve Trim5 genes (Sawyer
et al., 2007; Si et al., 2006), while rats have three and mice have up to
eight (Tareen et al., 2009). Two of the mouse Trim5 genes were
previously known as Trim12 and Trim30. However, phylogenetic
analysis of these two genes and their paralogs (named Trim12-1, 12-2,
and Trim30-1, 30-2, 30-3, and 30-4) revealed that they all are, in fact,
homologs of Trim5 (Tareen et al., 2009). One of these mouse Trim5
genes, knownas Trim30, has been shown tonegatively regulate Toll-like
receptor (TLR)-mediated nuclear factor-kappaB (NF-kappaB) activation
by targeting TAB2 and TAB3 for degradation (Shi et al., 2008). Although
at the time, it was not appreciated thatmouse Trim30was a homolog of
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that Trim5α might have additional roles in innate immunity besides
direct recognition of retroviral capsids.
TAB2 and TAB3 are two adaptor proteins that play a key role in
activation of a kinase calledTAK1(TGF-beta activatedkinase 1) (Cheung
et al., 2004; Takaesu et al., 2000; Yamaguchi et al., 1995), resulting in
downstream activation of members of the mitogen activated protein
kinase (MAPK) family that are indispensable for several signaling
pathways such as NF-kappaB, IL-1beta, TNF, and TLR signaling
(reviewed in Chen et al., 2006; Delaney and Mlodzik, 2006). Upstream
ligand–receptor interactions are transmitted via TAK1 to downstream
MAPKs aswell as to NF-kappaB through phosphorylation of its inhibitor
IkB kinase (IKK) (Chen, 2005; Shim et al., 2005). Expression of mouse
Trim30 targets both TAB2 and TAB3, thus abrogates the activation
of TAK1 and the subsequent downstream activation of NF-kappaB (Shi
et al., 2008). These observations raise the question of whether this
function is conserved across Trim5α homologs from all mammals.
Here, we ﬁnd that the ability to affect levels of TAB2 is a conserved
function of Trim5α in mice and humans. Use of proteasomal inhibitors
aswell as RING domain zincﬁngermutants of Trim5α demonstrate that
Trim5α affects TAB2 levels through amechanism that is independent of
E3 ubiquitin ligase activity. The ability to affect TAB2 levels is present in
human and mouse Trim5α, but not in rhesus Trim5α. Like mouse
Trim5α, human Trim5α also abrogates TAB2-dependent NF-kappaB
activation. However, unlike mouse Trim5α, both human and rhesus
Trim5α are able to independently activate NF-kappaB-driven transcrip-
tion. By deﬁning the domains of human Trim5α necessary for these
functions, we were able to genetically separate the ability of Trim5α to
affect TAB2 levels from its ability to activate NF-kappaB. These
independent abilities of Trim5α did not require the adaptively evolving
retroviral capsid recognizing PRY-SPRY domain. Our results demon-
strate functions of Trim5α that are not dependent on recognizing the
retroviral capsid andmay point to an independent role of Trim5α in the
innate immune response to pathogens.
Results
A conserved function for murine Trim5α paralogs and human Trim5α:
Affecting levels of TAB2
The mouse Trim5 locus consists of eight Trim5 genes, ﬁve of which
are predicted to encode the full-length splice variant homologous to
Trim5α in humans. These full-length genes are known as Trim12-1,
Trim12-2, Trim30, Trim30-2, and Trim30-3 (Tareen et al., 2009). Of these,
we have been able to clone and express three frommouse RNA, namelyTAB2
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TAB2 and TAB3 for degradation (Shi et al., 2008), we asked if this
function is conserved across other mouse Trim5α paralogs.
We cotransfected 293T cellswith constant amounts of TAB2 alone or
in the presence of increasing amounts of the TRIM gene being tested
(Fig. 1). Consistent with what has previously been shown (Shi et al.,
2008),we found that the levels ofmurineTAB2decreasewith increasing
amounts of Trim30. Trim12-2 andTrim30-3behaved the samewaysuch
that increasing amounts of Trim12-2 or Trim30-3 resulted in a decrease
in the levels of TAB2 (Fig. 1). This concentration-dependent manner in
which TAB2 levels are affected is speciﬁc to mouse Trim5α paralogs
since Trim34-1, the next closest related gene that sits near the Trim5
locus, but is not one of the Trim5α genes (Tareen et al., 2009), was not
able to affect the levels of TAB2 (Fig. 1, right side). These results show
that affecting the levels of TAB2 is a conserved function of mouse
Trim5α paralogs.
Since mouse Trim5α paralogs are able to affect protein levels of
TAB2, we asked if this activity is also present in human and rhesus
Trim5α proteins. Cotransfecting 293T cells with human TAB2 in the
presence of increasing amounts of human Trim5α or empty vector
(LPCX) showed that increasing amounts of human Trim5α results in
lower levels of human TAB2 (Fig. 2A). However, a closely related TRIM
protein in humans, Trim22, was not able to affect TAB2 levels, even in
exceedingly large amounts of Trim22 being expressed (Fig. 2A).
Human Trim5α was also able to affect the levels of mouse TAB2
(Fig. 2A, right side) and rhesus TAB2 (data not shown), even though
rhesus Trim5α was unable to affect the levels of either rhesus or
human TAB2 (Fig. 2A). These results show that targeting TAB2 is
present among human and murine Trim5α homologs but may not be
a universal property of Trim5 since we did not observe it for the
rhesus homolog.
To understand the mechanism of how human Trim5α affects TAB2
levels, we asked if a proteasomal pathway requiring E3 ubiquitin
ligase activity of Trim5α was involved. We generated a Trim5α
protein that contains a mutated zinc ﬁnger in its RING domain by
substituting cysteine at position 35 to alanine (Trim5α-C35A).
Trim5α-C35A was still able to affect TAB2 levels (Fig. 2B) indicating
that an intact zinc ﬁnger within the RING domain of Trim5α is not
required for affecting TAB2, thus making it unlikely that the effect is
through an E3 ubiquitin ligase activity of Trim5. We further assessed
this by treating cells with either proteasomal inhibitors or lysosomal
inhibitors. We found that Trim5α still is able to affect TAB2 levels in
the presence of proteasome inhibitors (Fig. 2C). We observed a very
slight effect of lysosomal inhibitors compared to no drug control is
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Trim5α or with empty vector LPCX were transfected (indicated by gray triangle; increasing gradient of 0.06 μg, 0.2 μg, 0.6 μg DNA transfected per lane). (B) 293T cells were
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be consistent over a range of Trim5 levels (Fig. 2C). Taken together,
these ﬁndings suggest that the ability of Trim5α to target TAB2 for
degradation is conserved across mice and humans (although not
present in the rhesus homolog of Trim5) and that the ability to affect
TAB2 levels is not linked to proteasomal degradation.
Human and rhesus Trim5α induces NF-kappaB reporter activity
A downstream result of TAB2 signaling is activation of NF-kappaB.
Mouse Trim30, one of the mouse Trim5α paralogs, was previously
shown to negatively regulate TAB2-dependent NF-kappaB activation by
targeting TAB2 for degradation (Shi et al., 2008). We askedwhether the
conserved ability of human and mouse Trim5α to target TAB2 also
resulted in similar outcomes when it came to regulation of NF-kappaB.
Using an NF-kappaB-inducible luciferase reporter gene we assessed the
effects of overexpressing human or mouse Trim5α homologs in 293T
cells. As expected, expressing TAB2 by itself was sufﬁcient to activate
NF-kappaB-driven transcription (Fig. 3A). Surprisingly, however, the
expression of human Trim5α by itself resulted in activation of NF-
kappaB-driven transcription, which was not the case with the mouse
Trim5α paralogs we tested (mouse Trim12-2, Trim30, Trim30-3)
(Fig. 3A). Furthermore, the closely related human Trim22 failed to
activate the NF-kappaB-inducible reporter gene (Fig. 3A).
Since human, but not mouse Trim5α, is able to activate the NF-
kappaB-inducible reporter gene expression, we asked if this ability is
conserved for other primate Trim5α orthologs. We found that both
human and rhesus Trim5α are able to activate NF-kappaB in a dose-
dependent manner (Fig. 3B), suggesting that this ability may be more
important for primate Trim5α than is the ability to affect TAB2 levels.
Interestingly, at higher concentrations, human and rhesus Trim5α
responded differently such that human, but not rhesus, Trim5α reached
saturation and resulted in a drop in NF-kappaB activation (Fig. 3B). A
naturally occurring splice variant of human Trim5 that lacks theretroviral capsid recognizingPRY-SPRYdomain, Trim5γ (Trim5gamma),
was also able to activate NF-kappaB, albeit not as strongly as human
Trim5α (Fig. 3B). As before, Trim22 expression had little to no effect on
NF-kappaB regulationeven though itwas expressed at higher levels than
Trim5α (Fig. 3B, bottom). Taken together, these ﬁndings indicate that
activation of NF-kappaB-driven transcription is conserved among
human and rhesus Trim5α orthologs, and most likely across primate
Trim5α orthologs, and that the adaptively evolving PRY-SPRY domain of
Trim5α is not required for this activity.
The ability of humanTrim5α to regulate TAB2 levels, to activateNF-kappaB,
and to recognize retroviral capsids are genetically separable
Trim5α as a restriction factor recognizes the viral capsid through its
C-terminal PRY-SPRY domain. The genetic conﬂict arising from this
interaction has caused adaptive evolution of Trim5α to take place
mostly in its PRY-SPRYdomain.Wehypothesized that Trim5αmust use
distinct domains for its conserved functions of targeting TAB2 and for
activatingNF-kappaB than for recognizing the retroviral capsid. First,we
tested this hypothesis using Trim5γ, which encodes all but the PRY-
SPRY domain of Trim5α and is not able to restrict retroviral capsids
(Stremlau et al., 2004). Increasing amounts of Trim5γwas able to affect
TAB2 levels compared to increasing amounts of empty vector LPCX
(Fig. 4B). Thus, the domain necessary for recognition of retroviral
capsids is not required for the activity of Trim5α in affecting TAB2 levels.
To narrow in on the domains of Trim5α necessary for affecting TAB2
levels, we designed several chimeras between Trim5α and its close
relative Trim22, which does not affect TAB2 levels (Fig. 4A). When the
RING domain of Trim22 was swapped in place of the Trim5α RING
(Trim22R-5α), the ability of Trim5α to affect TAB2 levels was lost
(Fig. 4C), indicating that the RINGdomain of Trim5α is necessary.When
the Trim5 RING was swapped into Trim22 in place of the Trim22 RING
(Trim5R-22), this chimera did not gain the ability to affect TAB2 levels
(Fig. 4C), indicating that the RING of Trim5α is not sufﬁcient. Onlywhen
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Fig. 3. Primate but not mouse Trim5α activates NF-kappaB-driven reporter expression.
(A) 293T cellswere cotransfectedwith an NF-kappaB-driven Luciferase reporter construct
(NF-kappaB-LUC, 0.5 μg DNA transfected per lane) together with 0.5 μg DNA of either
empty vector LPCX, human TAB2, human Trim5α, human Trim22, or one of the mouse
Trim5α paralogs (Trim12-2, Trim30, Trim30-3). (B) 293T cellswere cotransfectedwith an
NF-kappaB-driven Luciferase reporter construct (0.5 μg DNA per lane) together with
increasing amounts of human Trim5α, or human Trim5γ, or human Trim22, or rhesus
Trim5α, or empty vector LPCX. Luciferase expression is plotted on the y-axis as fold
induction relative to reporter gene plus empty vector LPCX. The DNA transfection ratio of
LPCX or TRIM relative to NF-kappaB-LUC is plotted on the x-axis (3-foldmeans 1.5 μg DNA
of TRIM vs. 0.5 μg of TAB2, and so on.) Protein expression was compared using anti-HA
antibody. The immunoblots on the left and the right are to compare protein expression for
the x-axis transfection ratios of 1 and 3, respectively. The doublet band of Trim5γ has been
reported before (Stremlau et al., 2004).
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was the ability to affect TAB2 gained (Fig. 4C). These ﬁndings indicate
that both the RING and Bbox of Trim5 are sufﬁcient in a Trim22
backbone to gain the ability to affect TAB2 levels. Moreover, although
the RING domain of Trim5 is necessary, E3 ubiquitin ligase activity and
an intact zinc ﬁnger in the RING domain is not required as shown by the
proteasomal inhibitors and the C35Amutant (Figs. 2B and C). Therefore,
despite the rapid evolution of PRY-SPRY, Trim5α appears to use itsmore
conserved domains to maintain the ability to target TAB2 and affect its
levels.
We then asked if the ability of Trim5α to affect TAB2 levels is
independent of its ability to activate NF-kappaB by testing these same
domain swaps for their ability to activate an NF-kappaB reporter. Asdescribed earlier (Fig. 3B), Trim5γ is able to activate NF-kappaB, albeit
not as strongly as Trim5α (probably due to expression differences—see
Western blot belowFig. 5A). This indicates that the PRY-SPRY domain of
Trim5α is not required to activate NF-kappaB-driven reporter gene
expression (Fig. 5A). The Tr22R-5α chimera constructed between
human Trim5α and Trim22 (Fig. 4A) showed that the RING domain of
Trim5α was necessary to activate NF-kappaB (Fig. 5A). Interestingly,
however,while theRINGandBbox of Trim5αwere sufﬁcient to regulate
TAB2, theywerenot sufﬁcient to activateNF-kappaB (Tr5RB-22 chimera
in Figs. 5A andB). Furthermore,while the zincﬁnger of theTrim5αRING
domain was dispensable for regulating TAB2, it was required for
inducingNF-kappaBbecause the C35Amutant of Trim5α lost this ability
(compare Fig. 5B with Fig. 2B). These results genetically separate the
ability of Trim5α to affect TAB2 levels and to activate NF-kappaB-driven
transcription.
The interplay of the independent abilities of Trim5α to affect TAB2 levels
and to activate NF-kappaB
We next investigated how the ability of Trim5α to reduce levels of
TAB2 affects NF-kappaB activity. To do so we ﬁrst asked if Trim5α, by
affecting TAB2 levels, would abrogate TAB2-dependent NF-kappaB
activation. Overexpression of either Trim5α or TAB2 by itself activates
NF-kappaB-driven reporter gene expression, with higher TAB2-
dependent activation (Fig. 6A). However, adding Trim5α together
with TAB2 brings NF-kappaB activation back down to the levels of
Trim5α only, consistent with the decrease in the protein levels of
TAB2 (Fig. 6A). Therefore, human Trim5α, similar to mouse Trim30,
abrogates TAB2-dependent NF-kappaB activation.
Dose–response curves showed that with increasing amounts of
human Trim5α, the amount of NF-kappaB activation eventually began
to decrease, although this did not occur with rhesus Trim5α (Fig. 3B).
We hypothesized that this drop in NF-kappaB was due to human
Trim5α being able to decrease endogenous levels of TAB2, thus
affecting TAB2-dependent NF-kappaB activation. Accordingly, we
would expect rhesus Trim5α, which has no effect on human TAB2
levels, to have no effect on TAB2-dependent NF-kappaB activity. We
tested this hypothesis by looking at the dose-responsive effects of
Trim5α on TAB2-dependent activation of NF-kappaB. We transfected
a constant amount of a TAB2-expressing plasmid along with
increasing amounts of Trim5α or empty vector and then measured
the activity of an NF-kappaB reporter. We observed an additive effect
of TAB2 and Trim5α on NF-kappaB activation at low Trim5α levels,
followed by a drop in response to increasing amounts of Trim5α,
resulting from more degradation of TAB2 and thus stronger
abrogation of TAB2-dependent NF-kappaB activation (follow the red
line in Fig. 6B). When we used increasing amounts of rhesus Trim5α
that only activates NF-kappaB but does not speciﬁcally target TAB2
(performs like empty vector LPCX), we only observed an increase in
NF-kappaB activation but no abrogation of TAB2-dependent NF-
kappaB activation (follow the blue line in Fig. 6B). These results are
consistent with what we observed earlier in the absence of
exogenously expressed TAB2 (Fig. 3B). In contrast, with increasing
amounts of the Tr5RB-22 chimera that affects TAB2 but does not
activate NF-kappaB, we observed a dramatic drop in TAB2-dependent
NF-kappaB activation (follow the orange line in Fig. 6B). These
ﬁndings show that Trim5α regulates NF-kappaB activation by at least
two independent mechanisms: activation of NF-kappaB by Trim5α
itself and abrogation of TAB2-dependent NF-kappaB activation due to
Trim5α targeting TAB2 for lysosomal degradation.
Discussion
Herewe describe functions of human Trim5α that do not depend on
recognition of retroviral capsids. We show that human Trim5α, similar
to itsmouse homolog Trim30, targets TAB2 for degradation, resulting in
Trim5α
Trim22
Tr5R-22
Tr5RB-22
Tr22R-5α
Trim5γ
kDa
80
60
50
40
RING CC PRYSPRYBbox
LPCX
TAB2TAB2
Trim5γ
TAB2
Trim5γ
Actin
Tr
im
5γ
A B
TAB2
Trim2
2
TAB2
Tr22R
-5α
TAB2
Tr5R-
22
TAB2
Tr5RB
-22
TAB2
Trim5
α
TAB2
Trim
Actin
C
Fig. 4.Human Trim5α affecting TAB2 levels is dependent on its RING and B-box domains but not on its PRY-SPRY domain. (A) Diagram showing domains of Trim5α, Trim5γ, Trim22,
and the chimeras constructed between Trim5 and Trim22. Trim22R-5α indicates Trim22 RING in a Trim5α background. Trim5R-22 indicates Trim5 RING in a Trim22 background.
Trim5RB-22 indicates a Trim5 RING and B-box in a Trim22 background. (B) 293T cells were cotransfected with constant amounts of human TAB2 (2 μg DNA per lane) and with
increasing amounts of either empty vector LPCX or with human Trim5γ (gradient of 0.06 μg, 0.2 μg, 0.6 μg DNA per lane). The doublet band of Trim5γ has been reported before
(Stremlau et al., 2004). (C) 293T cells were cotransfected with constant amounts of human TAB2 and with increasing amounts of either human Trim5α, or human Trim22, or the
chimeras Trim22R-5α, Trim5R-22, or Trim5RB-22. DNA transfected same as panel B. Diagrams of each Trim construct is shown below their respective immunoblot for convenience.
All constructs contain HA tags. Lysates were probed with anti-HA antibodies, then stripped and reprobed with anti-actin.
117S.U. Tareen, M. Emerman / Virology 409 (2011) 113–120abrogation of TAB2-dependent NF-kappaB activation. However, unlike
mouse Trim30, human and rhesus Trim5α are able to activate NF-
kappaB-driven reporter gene expression in a dose-dependent manner.
Using splice variants, chimeras, and mutants, we show that human
Trim5α uses distinct domains for the distinct abilities of affecting TAB2
levels, regulating NF-kappaB, and recognizing retroviral capsids. We
speculate that the induction of NF-kappaB is the more critical of these
activities since it is common between the two primate Trim5 genes
tested.
Viruses either escape from or harness innate immunity pathways in
order to continue their life cycle. For example, NS1proteinof inﬂuenzaA
virus prevents NF-kappaB-dependent interferon signaling by binding
viral dsRNA andpreventing PKRactivation (Wang et al., 2000). Based on
work reported here, Trim5α, by regulating TAB2 levels or activating NF-
kappaB, could be involved in controlling a response to viral infection at
various stages. Implications of a TRIM protein in signaling events that
affect viruses are not without precedent. For example, Trim25, which
also has RBCC and PRY-SPRY domains, is able to induce IFN signaling
against RNA viruses by activation of RIG-I through K63 polyubiquitina-
tion (Gack et al., 2007). In this example, the antiviral properties of
Trim25 appear to be directly linked to its role in RIG-I signaling.
Interestingly, human T-cell lymphotropic virus type 1 (HTLV-1) appears
to hijack TAB2-dependent signaling through induction of TAB2 levels
using its Tax oncoprotein, resulting in transcriptional activation and
transformation (Boxus et al., 2008; Suzuki et al., 2007; Yu et al., 2008).
It is unclear why a rapidly evolving antiviral factor such as Trim5α
would be co-opted to play a key role in regulating signaling or vice versa.
One explanation may be that the ability of Trim5α to function as an
antiviral factor is linked to its role in signaling and that these two roles
are inseparable even though we show here that genetically they are
separable. The recent ﬁnding that restriction by Trim5α in thecytoplasmic bodies relies on the presence of p62/sequestosome-1, an
interferon-inducible gene involved in signalingpathways such as TRAF6
and NF-kappaB (O'Connor et al., 2010), supports a role of cell signaling
in the Trim5α restriction pathway. Furthermore, it is possible that
Trim5α signaling and restriction functions are actually linked in some
way since infection of cells with a retrovirus that is recognized by
Trim5α leads to the degradation of Trim5α (Rold and Aiken, 2008).
Thus, the signaling mechanisms induced by Trim5α could be a cellular
response to a viral infection where the “recognition” event is the loss of
Trim5α in the cell, which then leads to the absence of those constitutive
Trim5α signals.
The ability of Trim5 to target TAB2 and to upregulate NF-kappaB
appears to be independent of the PRY-SPRY domain (Figs. 3 and 4);
however, we cannot rule out the possibility that the PRY-SPRY domain
might be involved in moderating these activities. The fact that the
PRY-SPRY domain is used by Trim5α for recognizing and binding to
the viral capsid and that this domain contains the region under most
positive selection indicates that Trim5α is able to maintain its other
functions while still being able to adaptively evolve in its PRY-SPRY
domain. The RBCC domains of Trim5α appear to be involved in the
TAB2 and NF-kappaB functions we describe here. Since these
functions most likely involve the formation of complexes with other
cellular proteins through protein–protein interactions, we would
expect evolution to select against amino acid changes that could
impede with these functions. Therefore, the functions of Trim5α in
TAB2 and NF-kappaB signaling could maintain the evolutionary
constraint seen in the RBCC domains of Trim5α. Interestingly, certain
amino acids in parts of the RBCC domains are also under positive
selection, although not as strongly and as dense as in the PRY-SPRY
(reviewed in Johnson and Sawyer, 2009). Whether these amino acids
speciﬁcally contribute to the abilities of Trim5α described here
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TAB2 levels, even though this ability is conserved in humans andmice,
could indicate a loss in the ability of rhesus Trim5α to target TAB2,
possibly due to amino acid differences in the RBCC domains between
human and rhesus Trim5α. It is possible that polymorphisms in
rhesus Trim5αwill affect this ability, but we have not yet tested other
alleles. Likewise, it is possible that human polymorphisms in Trim5α
will also affect these activities.
Using chimeras and mutants, we were able to separate the ability
of human Trim5α to affect TAB2 levels, from its ability to activate NF-
kappaB. The interplay of these two abilities (Fig. 6) suggests that
human Trim5α either upregulates NF-kappaB downstream of where
it targets TAB2 in the signaling cascade, that Trim5α is able to
upregulate NF-kappaB through a pathway that is independent of
TAK1 activation. NF-kappaB is regulated through two pathways
known as the canonical and noncanonical pathways (reviewed in
Skaug et al., 2009). TAK1 is involved in the canonical pathway where,
119S.U. Tareen, M. Emerman / Virology 409 (2011) 113–120upon TNF or IL-1beta stimulation, TAK1 activates IKK, which then
targets IkB proteins for degradation, thus allowing the p50/65 NF-
kappaB dimmer to enter the nucleus. In the noncanonical pathway,
CD40L stimulation results in the activation of the NF-kappaB inducing
kinase (NIK) and the IKKalpha subunit. The latter, in turn, targets
p100 for degradation, thus allowing the p52/Rel-B dimmer to enter
the nucleus. The reporter construct we used in our experiments for
NF-kappaB activation is sensitive to both of these pathways. It is also
possible that the seeming degradation of TAB2 by human Trim5α is an
epi-phenomenon that is simply a readout of a binding activity to TAB2
that is shared with rhesus Trim5α and which results in induction of
NF-kappaB in both cases.
Primates, rabbits, cats, and dogs have one copy of Trim5, whereas
rodents and cows have multiple copies of Trim5 in their locus (Schaller
et al., 2007;McEwan et al., 2009; Tareen et al., 2009; Sawyer et al., 2007;
Si et al., 2006). This diverse nature of the Trim5 locus among mammals
suggests that theremay be diverse strategies in balancing the abilities of
viral restriction with regulating TAB2 and NF-kappaB pathways. In the
case of rodents and cows, paralogous Trim5 gene expansions may be
selected for temporal and spatial sharing of duties; for example, certain
Trim5 paralogs may be expressed during certain stages of development
and take on functional responsibility. Alternatively, different Trim5
paralogs may complement one another by splitting different functions.
Interestingly, two of the mouse Trim5 paralogs, namely Trim12 and
Trim30-1, do not encode the PRY-SPRY domain (Tareen et al., 2009).
However, our ﬁndings that the PRY-SPRY is not required suggest that
mouse Trim12 and Trim30-1 may also be capable of negatively
regulating NF-kappaB activation by targeting TAB2 and TAB3 for
degradation, similar to Trim30. The fact that the functions for Trim5α
we describe here are present in mice and humans suggests that either
evolutionhasmaintained this function since thedivergenceof these two
species or that, although less likely, convergent evolution explains these
functions in mouse and human Trim5α.
One problem that rapidly evolving antiviral factors may face is how
they are able to adaptively evolve while maintaining sequence
conservation for conserved functions. Trim5α appears to have solved
this problem by using distinct domains to recognize retroviral capsids
versus regulating TAB2 and NF-kappaB signaling: the PRY-SPRY
recognizes the capsid and is free to rapidly evolve, while the remaining
domains are under evolutionary constraint in order to maintain the
functions described here. These functions of Trim5α may have
bestowed upon it multiple roles in innate immunity, thus possibly
explaining its maintenance over millions of years throughout mamma-
lian evolution even in the absence of retroviral recognition.
Materials and methods
Constructs
All constructs used for overexpression studies are N-terminally
tagged with an HA epitope and are cloned into retroviral mammalian
expression vectors pLNCX or pLPCX. Mouse and human TAB2 and TAB3
cDNAs were obtained from Open Biosystems. Mouse Trim5 paralogs
(namely Trim12-2, Trim30, and Trim30-3) as well as mouse Trim34-1
have been cloned from RNA from NIH3T3 cells as described (Tareen
et al., 2009). Rhesus Trim5αwasobtained from JosephSodroski. Human
Trim5α was obtained from the NIAID AIDS repository. Human Trim22
was previously described (Sawyer et al., 2007). Human Trim5γ and
Trim34 have been cloned fromRNA fromHeLa cells. Chimeras of human
Trim5 and Trim22 have been cloned by designing overlapping PCR
primers annealing to either the end of the RING domain (for RING only
chimeras as in Trim5RING22 or Trim22RING5) or the end of the Bbox
domain (for RING and Bbox chimeras as in Trim5RBbox22). C35A
mutant of Trim5α was constructed using QuickChange XL2 kit
(Stratagene). Human Trim5α SNPs were previously described (Sawyer
et al., 2006).Transient transfections
293T cells were plated at 106 cells/ml/well in a 12-well plate. The
next day, transfectionswere performed using 3 μl of TransIT (MirusBio)
per 1 μg of DNA according to the protocol. DNA in each well was kept
constant by adding empty vector (LPCX). Due to the differences in
turnover rates between the proteins being overexpressed, whenever
possible, the DNA amounts transfected were adjusted to match similar
protein levels. Cells were lysed 24 hours after transfection and
cytoplasmic extracts were made and prepared for Western blotting.
Proteasomal and lysosomal inhibitors
293T cells were transfected as described above. Proteasomal
inhibitors (10 μM MG132) or lysosomal inhibitors (20 mM NH4Cl and
0.1 mM leupeptin) were added 24 hours after transfection, and cells
were treated for 2 hours before they were lysed.
NF-kappaB–Luciferase reporter assays
293T cells were transfected (as described above) with appropriate
constructs as well as with pCEP4-NF-kappaB–Luc reporter construct
(Promega). At 24 or 48 hours after transfection, cells were trypsinized
and then lysedwith bright-glow luciferase reagent. Luciferase unitswere
read on plate reader.
Antibodies and cell lysis
Anti-HA was obtained from Covance. Anti-actin was obtained from
Sigma. Cells were lysed using 1% NP40-DOC lysis buffer in the presence
of 1× protease inhibitors EDTA free and 1× phosphatase inhibitors
(Roche). Nuclei were spun out, and lysates were quantiﬁed using
Bradford reagent. NuPage Bis–Tris gels and NuPage transfers were used
for Western transfers (Invitrogen).
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